Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 12/20 | 0.71 |
| ▸ | RAB9A | P51151 | 11/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.71 |
| ▸ | HPGD | P15428 | 5/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.66 |
| ▸ | GLA | P06280 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 1/20 | 0.66 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.66 |
| ▸ | MMP3 | P08254 | 1/20 | 0.62 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.62 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.62 |
| ▸ | RELA | Q04206 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.59 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6737766 | 0.98 | NPC1 (0.74) | NPC1RAB9ASMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL5638741 | 0.91 | NPC1 (0.59) | NPC1RAB9ASMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL74999 | 0.89 | NPC1 (0.90) | NPC1RAB9ASMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL9737564 | 0.89 | RAB9A (0.58) | NPC1RAB9ASMN1; SMN2HPGDMAPT | |
| SCHEMBL46424 | 0.89 | NPC1 (0.90) | NPC1RAB9ASMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL522555 | 0.89 | NPC1 (0.90) | NPC1RAB9ASMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL22858502 | 0.89 | NPC1 (0.90) | NPC1RAB9ASMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL5640017 | 0.87 | RAB9A (0.59) | NPC1RAB9ASMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL1105099 | 0.87 | NPC1 (0.85) | NPC1RAB9ASMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL4343181 | 0.87 | NPC1 (0.94) | NPC1RAB9ASMN1; SMN2HPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9859505-B2 | Charge-transporting molecular glass mixtures, luminescent molecular glass mixtures, or combinations thereof or organic light emitting diodes and other organic electronics and photonics applications | MOLECULAR GLASSES, INC. (US) | 2018-01-02 | — | — | US | disclosed |
| US-20150053894-A1 | Charge-transporting Molecular Glass Mixtures, Luminescent Molecular Glass Mixtures, or Combinations Thereof for Organic Light Emitting Diodes and other Organic Electronics and Photonics Applications | Molaire Consulting | 2015-02-26 | — | — | US | disclosed |
| US-20150053894-A1 | Charge-transporting Molecular Glass Mixtures, Luminescent Molecular Glass Mixtures, or Combinations Thereof for Organic Light Emitting Diodes and other Organic Electronics and Photonics Applications | Molaire Consulting | 2015-02-26 | — | — | US | disclosed |
| US-7229987-B2 | Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes | ELI LILLY AND COMPANY (US) | 2007-06-12 | — | — | US | disclosed |
| US-7229987-B2 | Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes | ELI LILLY AND COMPANY (US) | 2007-06-12 | — | — | US | disclosed |
| US-7229987-B2 | Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes | ELI LILLY AND COMPANY (US) | 2007-06-12 | — | — | US | disclosed |
| US-20050272718-A1 | Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes | AMMENN ET AL, JOCHEN | 2005-12-08 | — | — | US | disclosed |
| EP-1505968-A1 | MULTICYCLIC COMPOUNDS FOR USE AS MELANIN CONCENTRATING HORMONE ANTAGONISTS IN THE TREATMENT OF OBESITY AND DIABETES | ELI LILLY AND COMPANY (US) | 2005-02-16 | — | — | EP | disclosed |
| WO-2003097047-A1 | MULTICYCLIC COMPOUNDS FOR USE AS MELANIN CONCENTRATING HORMONE ANTAGONISTS IN THE TREATMENT OF OBESITY AND DIABETES | ELI LILLY AND COMPANY (US) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272718-A1 | Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes | MC1R, MC4R, MC5R | NPC1 457/4885RAB9A 1063/4885SMN1; SMN2 4137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.